In Brief: Preamendment Class III device classification
This article was originally published in The Gray Sheet
Executive Summary
Preamendment Class III device classification: FDA has received data from approximately 10% of manufacturers required to submit safety and effectiveness information by the Aug. 14 deadline under the agency's August 1995 call for data on pre-1976 Class III devices per section 515(i) of the FD&C Act ("The Gray Sheet" Aug. 21, 1995, p. 6). The data, for preamendment devices for which FDA has not yet issued a call for PMAs, will be used by the agency to determine which devices will remain in Class III and which can be downclassified. FDA's Office of Device Evaluation sent a letter the week of July 29 to 98 firms registered as manufacturers of the 17 devices covered by the Aug. 14 deadline, reminding them of the impending due date. For further information, contact ODE's Melpi Jeffries at 301/594-2186...
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.